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ABSTRACT 
In an open trial, patients with ICD-10 diagnosis of acute functional psychoses were administered 
injection Zuclopenthixol acetate (Acuphase) in the initial phase. Patients were rated with CGI, BPRS 
-24 item and UKU side effect rating scale at baseJine, 24 hours and 72 hours. Of the 120 patients 
recruited, 119 finished this part of the trial. The most common side effect was sedation, which was 
preferable as most of the patients were in the acute state. The issues concerning less dosing 
efficacy and the rapid onset of antipsychotic activity are discussed. 
Patients who had been administered zuclopenthixol acetate in the acute phase were maintained 
with injection zuclopenthixol decanoate (depot) starting at 72 hours over the baseline. Patients 
were assessed at 72 hours, one week, 2 weeks, 3 vseeks, 4 weeks and 8 weeks using the same 
instruments. The issues concerning the dosage and therapeutic efficacy are discussed. 
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Violence and aggression constitute a major 
problem in psychiatry. For a psychiatrist the main 
concern when working with such severely ill 
patients is to limit or prevent physical violence 
and disruptive behaviour. Earlier severely 
aggressive patients were confined to the custodial 
care system of mental hospitals. Today with the 
availability of different modes of treatment 
including pharmacotherapy and psychotherapy 
treatment of acutely violent and psychotic patients 
is made much effective and easier. Parenteral 
neuroleptics achieve a quicker onset of action and 
prevent non-compliance. Zuclopenthixol is one 
such neuroleptic drug belonging to the 
thioxanthene group. Zuclopenthixol acetate in thin 
vegetable oil ('viscoleo') when given 
intramuscularly has a rapid onset of action with 
sustained effect of 2-3 days duration 
(Hebenstreit,1990). Short acting parenteral 
neuroleptics such as haloperidol have a 
disadvantages as their duration of action is short. 
The long-acting depot preparation of 
zuclopenthixol is in the form of decanoate in 
vegetable oil. It is for intramuscular administration 
and has its therapeutic effects for 2 to 4 weeks. 
Zuclopenthixol decanoate has been found useful 
in the maintenance treatment of chronic 
psychoses namely schizophrenia (Wistedt et 
al.,1991). Depot injections overcome the 
problems of first pass metabolism by the liver 
and give a predictable and constant serum level. 
In addition the total number of injections over 
an extended period of weeks and months 
remains quite small and that enhances treatment 
compliance. The authors investigated 
Zuclopenthixol in an open prospective, 
multicentered study of acutely psychotic patients 
- to evaluate the safety and efficacy. 
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MATERIAL AND METHOD 
STUDY POPULATION AND SCHEDULE : 
One hundred and twenty patients were 
recruited satisfying the study criteria for inclusion 
in trial, after obtaining written informed consent. 
I, Before starting the study the protocol was duly 
cleared by the ethical committees of the three 
participating centres, namely Institute of 
Psychiatry and Human Behaviour (IPHB), Goa; 
KEM Hospital (KEM), Mumbai and National 
Institute of Mental Health and Neurosciences 
(NIMHANS), Bangalore. All patients were 
admitted in the hospital and were screened for 
other physical illnesses. Routine biochemical 
investigations including liver functions were 
done. A wash out period of 15 days was required 
to be given if they received a prior depot 
neuroleptic or it was 6 hours if other oral or 
parenteral neuroleptics were administered. All 
patients were started on zuclopenthixol acetate 
(Acuphase) supplied in 1 ml vials and 2 ml vials 
containing 50 mg/ml of zuclopenthixol acetate 
in thin vegetable oil (Viscoleo). The dose was 
repeated if required after 24 hours and if not a 
second dose was given after 72 hours. 
Concomitant medication with only 
benzodiazepines, antihistamines and hypnotics 
was permitted. Antiparkinsonian agents 
(trihexyphenidyl hydrochloride or promethazine) 
were added as and when required. No other 
psychotropic agents were administered. Ongoing 
medical therapy for chronic diseases (such as 
diabetes mellitus, hypertension and tuberculosis) 
whenever indicated was continued. 
At 72 hours, the 2nd dose of acuphase 
and the 1st dose of Zuclopenthixol decanoate 
(Depot) were given together; the dose of depot 
being the double of that of acuphase in mg. For 
most cases these values were 200 and 100 mg 
respectively. Subsequently depot injections were 
, administered at an interval of 2 weeks for the 
next 8 weeks in most cases as required by the 
study protocol. The dosage was kept constant 
as far as possible. The patients were seen in the 
outpatient during this phase of the trial. 
flENT OF ACUTE PSYCHOSES 
INCLUSION CRITERIA 
1. Age : 18-65 years. 
2. Either Sex 
3. Acutely ill psychotic patients (rated moderately 
ill or above on CGI) requiring psychopharmaco-
logical management diagnosed according to 
ICD-10 (CDDG-1992) : new cases or 
exacerbation of chronic psychoses. 
EXCLUSION CRITERIA 
1. Patients with epilepsy, clinically relevant 
physical or neurological illness. 
2. Patients with alcohol or drug abuse in the last 
one year or on other non-marketed text 
preparation. 
3. Pregnant and lactating women. 
INSTRUMENTS 
All patients were assessed for clinical 
status and side effects using the following 
instruments at baseline and after 24 hours, 72 
hours, 1week, 2 weeks, 3 weeks, 4 weeks and 8 
weeks: 
1. Clinical Global Impression Scale (CGI-S): 
This brief instrument has been developed by 
NIMH, USA as a ready reckoner of psychiatric 
status (Guy, 1976). Another version of this 
scale is called Clinical Global Impression of 
Improvement CGI-I. These scales have been 
used widely in western countries as well as in 
India. Both were used in this study. 
2. Brief Psychiatric Rating Scale (BPRS): 
This is a 24 item interviewer-rated 
questionnaire widely use for monitoring 
clinical improvement. Originally developed by 
Overall and Gorham (1962), this instrument 
has been used extensively in various studies 
in India and abroad. 
3. UKU Side Effect Rating Scale (UKU): 
This interviewer-rated instrument is divided 
into 4 categories of side effects viz. 
psychiatric, neurologic, autonomic and others 
(miscellaneous). This was developed by 
Scandinavian Psychopharmacology Society 
(Lingjaerde et al.,1987) and has been used in 
various Indian and international studies. 
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GENERAL FEATURES 
Results : 
The mean age of the patients was 32.1 
±11.1 years. Sixty-two (51.7%) were males. The 
average duration of the index psychotic episode 
was 14.9 weeks. 
Table 1 shows the diagnostic break-up. 
The most major diagnostic groups were acute 
polymorphic psychosis with features of 
schizophrenia and paranoid schizophrenia (26% 
each). Other major groups were bipolar affective 
disorder (BPAD)-mania with psychotic features 
(13%), undifferentiated schizophrenia (11%) and 
manic episode with psychotic features (8%). 
Table 2 describes the dropouts. A total of 
33 dropouts occurred till the end of depot 
medication (8 weeks). The common causes were 
inadequate response in 14 (11.7%) and comorbid 
problems including emergent depression in (10%). 
TABLE 1 
DIAGNOSTIC BREAK-UP (N=120) 
Diagnosis 
Acute polymorphic psychosis without 
features of schizophrenia 
Acute polymorphic psychosis with 
features of schizophrenia 
Acute schizophrenia like psychosis 
Acute psychosis with predominant 
delusions 
Manic episode with psychotic feature 
BPAD-mania with psychotic feature 
Paranoid Schizophrenia 
Undifferentiated Schizophrenia 
Delusional disorder 
Psychosis NOS 
Total 
Frequency 
7 
31 
7 
1 
9 
16 
31 
13 
1 
4 
120 
% 
5.8 
25.8 
5.8 
0.8 
7.5 
13.3 
25.8 
10.8 
0.8 
3.3 
100 
TABLE 2 
DETAILS OF DROPOUTS (N=33) 
Observed reason 
1) Inadequate response to treatment 
2) Comorbid problems including emergent 
depression 
3) Side effect other than depression 
4) Discontinued without appropriate reasons 
Number 
14 
12 
3 
4 
DOSING PATTERN 
The majority (114, 95%) received 100 
mg acuphase in their first injection. Only 5 (4.2%) 
NDES et at. 
received 50 mg acuphase as the first dose. At 
72 hours the majority (97, 80.8%) received 100 
mg as their second dose of acuphase, 20 (16.7%) 
needed only 50 mg of acuphase as the second 
dose and only 2 (1.7%) needed 150 mg of 
acuphase at 72 hours. Sixteen (13.3%) required 
an additional injection of 100mg acuphase within 
first 72 hours. 
At 72 hours all 119 patients received 200 
mg of Zuclopenthixol depot along with their 
second dose of acuphase. The patients were 
given depot injections at two weekly intervals 
subsequently till the end of the trial (8 weeks). 
Twenty (16.7%) of patients received 400 mg of 
zuclopenthixol decanoate in their subsequent 
depot injections. Eight (6.7%) received 600 mg 
as their depot injections in third and fourth 
dosage. Rest (91,75.8%) received 200 mg depot 
in all subsequent injections. 
RESULTS PERTAINING TO ZUCLOPENTHIXOL 
ACETATE (ACUPHASE) 
There was only one dropout till this stage 
of the trial and 119 patients' data are available. 
Table 3 describes the CGI-S findings. Only one 
patient was rated as mildly ill at the baseline and 
this happened by mistake. The number of 
patients in the category of 'severely ill' dropped 
from 66 (55%) at baseline to 25 (20.8%) at 72 
hours. Alongside there was an increase in the 
category of 'mildly ill' (0.8% to 15%) over the 
same period. These changes were found to be 
statistically significant. 
TABLE 3 
C.G.I.-S FINDINGS WITH ACUPHASE (N=119) 
Severity of illness 
Normal 
?Mentally ill 
Mildly ill 
Moderately ill 
Markedly ill 
Severely ill 
Extremely ill 
Missing Values 
Baseline(intake) 
0(0) 
0(0) 
1(0.8) 
14(11.7) 
35(29.2) 
66(55) 
4(3.3) 
0(0) 
24 hrs. 
0(0) 
0(0) 
10(8.3) 
29(24.2) 
42(35) 
39(32.5) 
0(0) 
0(0) 
72 hrs. 
2(17) 
0(0) 
18(15) 
25(20.8) 
48(40) 
25(20.8) 
1(0.8) 
1(0.8) 
Significance of 
Difference (chi-square) 
1) Between baseline & 24 hrs 70.42 df=12 p<0.01 
2) Between baseline & 72 hrs.55.17 df=20 p<0.01 
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CGI-I showed a similar trend of increase 
in the categories of 'very much improved' and 
'much improved'. Put together about 27% were 
found to be in these two categories at 24 hours 
and this figure increased to 34% at 72 hours. 
BPRS also showed a corresponding significant 
drop in overall scores. The mean value 
decreased from 77 at baseline to 63 at 24 hours 
and 58 at 72 hours. All these changes also were 
statistically significant. 
RESULTS PERTAINING TOZUCLOPENTHIXOL 
DECANOATE (DEPOT) 
The end of the trial for acuphase was 
the beginning of the trial for depot. Therefore 
the baseline for assessment started at 72 hours 
for depot. Eighty-seven (72.5%) patients 
completed the trial (8 weeks). Patients continued 
to improve with depot zuclopenthixol. Table 4 
shows the CGI -S findings. At the baseline about 
61 % were included in the categories of 'markedly 
ill and 'severely ill'. At 4 weeks only 13% and at 
8 weeks only 11 % were rated in those categories. 
TABLE 4 
CGI-S FINDINGS WITH DEPOT (N=87) 
Severity of 
illness 
Normal 
? Mentally ill 
Mildly ill 
Moderately ill 
Markedly ill 
Severely ill 
Extremely ill 
Missing Values 
Baseline 
72 hours 
2(1.7) 
0(0.0) 
18(15.0) 
25(20.8) 
48(40.0) 
25(20.8) 
1(0.8) 
1(0.8) 
4 weeks 
12(10.0) 
16(13.3) 
32(26.7) 
21(17.5) 
9(7.5) 
6(5.0) 
0(0.0) 
24(20.0) 
8 weeks 
16(13.3) 
30(25.0) 
18(15.0) 
10(8.3) 
9(7.5) 
4(3.3) 
0(0.0) 
33(27.5) 
Significance of difference (chi-square) between 
1) baseline & 4 weeks: 58.39; df=20; p<0.001 
2) baseline & 8 weeks. 35.47, df=20; p<0.017 
Alongside the categories of 'normal' and 
'questionably mentally ill' recorded a steady 
increase in the ratings (from 2% to 23% and 48% 
respectively). All these changes were found 
statistically significant. 
On CGI-I also a steady improvement 
was noted. The category of "very much 
improved" was rated in 10% of the cases at the 
baseline, in 24% at 4 weeks and in 35% at 8 
weeks. These changes were found significant 
only between the baseline and 4 weeks but not 
between the baseline and 8 weeks. 
The findings on BPRS showed a similar 
pattern. The mean total score of 58 at the 
baseline dropped to 39 at 4 weeks and to 36 at 8 
weeks. These changes were also found 
statistically significant. 
SIDE EFFECTS 
Apart from the sub group of neurologic 
side effects the other three sub groups of UKU 
side effects rating scale did not show much 
findings. There were few exceptions. 
In the 'psychic' sub group at 24 hours 
87 patients (72.5 %) showed increased sedation 
whereas 61 (50.8%) complained about the same 
at 72 hrs. As the trial progressed this complaint 
came down very considerably (e.g. at the end of 
8 weeks only 3 (2.5%) patients complained of 
increased sedation). 
Depression and asthenia were the other 
side effects that showed an increase as the trial 
progressed. While at 72 hours only 3 patients 
(2.5%) complained of depression and one (0.8%) 
of asthenia, these number progressed to 18 
(15%) in each category at the end of 8 weeks. 
TABLE 5 
NEUROLOGIC SIDE EFFECTS WITH ACUPHASE & DEPOT 
(% of patients having side effects) 
Visits (Time of Visit) 
Tremor 
Rigidity 
Akinesia/Hypokinesia 
Dystonia 
Hyperkinesia 
Akathisia 
1 (intake) 
0 
1.7 
1.7 
0 
0 
0 
2 (24 hours) 
7.5 
9.2 
9.2 
7.5 
0 
0 
3 (72 hours) 
15.7 
21.8 
24 4 
11.8 
0 
0 
4 weeks 
135 
26 
21.9 
3.1 
1 
5.2 
8 weeks 
8 
26.4 
23 
0 
1.1 
4.6 
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There were very few autonomic side 
effects. Increased salivation was the commonest 
affecting 5 (4.2%) to 8 (6.7%) patients between 
72 hours and 3 weeks. Orthostatic dizziness was 
found only in 2.5% of patients. Micturition 
difficulties were seen only in one patient. 
In the other section only headache was 
worth mentioning affecting 3 patients (2.5%) 
between the first and second weeks. 
Neurologic side effects are depicted in 
table 5. About 8% had tremors at 24 hours, 16% 
at 72 hours, 14% at 4 weeks and 8% at 8 weeks. 
Rigidity was more common affecting 10% at 24 
hours, 22% at 72 hours and 20% at 4 and 8 
weekly assessments. Hypokinesia had a similar 
pattern. Dystonia was more common in the 
beginning (8% at 24 hours and 11 % at 72 hours) 
but it affected only 3% at 4 weeks and none at 8 
weeks. Akathisia was absent in the beginning 
but was found later to affect 5% of patients at 4 
weeks and also at 8 weeks. Hyperkinesia was 
rare, affecting only 1% at the end of 4 weeks 
and at 8 weeks. 
DISCUSSION 
In this multicentered open trial of 
zuclopenthixol the efficacy of two preparations 
were evaluated. It was found that injection 
zuclopenthixol acetate in thin vegetable oil 
(viscoleo) was effective in bringing down the 
severity of psychosis in acute psychotic conditions 
within 72 hours. This efficacy was evident using 
CGI-S, CGI-I and BPRS-all three instruments. 
This was achieved with just one injection of 
acuphase. Only 16 (13.3%) patients needed 
another injection of acuphase within 72 hours. This 
finding is consistent with earlier reports of 
acuphase's efficacy in acute psychosis (Amdisen 
et al.,1986 & 1987; Selasberg & Barr, 1991). 
Acutely Psychotic patients are often 
given aqueous parenteral neuroleptics (such as 
Haloperidol) during the initial days of treatment. 
As the effect of such preparations is short lasting 
several injections are often given during one 
24-hour period. Apart from causing additional 
pain and attendant risk of developing injection-
NDES et al. 
related complications, this system of giving 
multiple injections disrupts the patients-staff 
relationship. Therefore a parenteral neuroleptic 
with rapid onset of action and longer duration of 
effect is likely to be a better alternative. 
Zuclopenthixol acetate as acuphase does just that 
(Hebenstreit, 1990; Babon & DeBleeker, 1990). 
No local side effects or reactions were 
noted with acuphase (Baastrup et al.,1992). 
Dystonias were observed in few patients and 
were often mild unlike the severe dystonias seen 
with other potent antipsychotic drugs (Matar et 
al.,1990). Rigidity and hypokinesia were noted 
in less than a quarter of the patients as reported 
earlier (Korner et al.,1993). Sedation was a 
significant side effect with acuphase, which was 
desirable in the acute phase of the illness. Babon 
and DeBleeker (1990) have reported similar 
findings. Autonomic side effects were low as also 
reported by Ivanov et al. (1992). 
Once the acutely ill patients were 
stabilized with acuphase they were shifted to 
injection zuclopenthixol decanoate in vegetable 
oil (depot). At 72 hours after intake, one injection 
of acuphase and a double dose depot injection 
were given together in the same syringe. This 
made the treatment easier, acceptable and 
facilitated compliance with a monotherapeutic 
regime (Hebenstreit, 1990). Over the period of 
next 8 weeks depot zuclopenthixol was found to 
be effective in controlling the psychotic condition 
as indicated by periodic assessments. Previous 
studies have reported similar findings (Denker et 
al.,1980; Ahlforsetal.,1980; Wistedtetal., 1991). 
During the entire schedule for depot 
medication most of the patients showed an 
improvement in their side effects profile. 
Sedation in particular came down significantly 
and so did tremor and dystonia. However rigidity 
and hypokinesia continued to effect about a 
quarter of the patients. Overall the side effects 
were mild as reported earlier (Hebenstreit, 1990). 
Depression and asthenia were emergent 
side effects during the period of depot medication 
and this side effect has not been discussed 
adequately in previous literature. Few patients 
needed to be discontinued from the trial because 
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they became quite depressed during the trial. 
This area merits future research. 
Future studies would do well to include 
double blind cross over placebo-controlled 
designs across various psychotic conditions and 
age groups. 
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